Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

Benzinga · 2d ago
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.